

Oncopeptides announces the Nomination Committee

Stockholm – November 22, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the composition of the Nomination Committee has been established.

According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2025 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of the end of the third quarter 2024 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.

The Nomination Committee in respect of the annual general meeting 2025 consists of the following persons who together represent approximately 23 percent of the number of shares and votes in the company based on the shareholder information at end of September 2024.

- Staffan Lindstrand, appointed by HealthCap VI L.P.
- Jonas Brambäck, appointed by Jakob Lindberg
- Anna Henricsson appointed by Handelsbanken Funds
- Per Wold-Olsen, the Chairman of the Board

The Nomination Committee's proposals will be presented in the Notice to the annual general meeting 2025 and on Oncopeptides' website, www.oncopeptides.com.

Shareholders who wish to submit proposals to the Nomination Committee can do so by sending an e-mail to info@oncopeptides.com (subject "Nomination Committee") or by letter posted to Oncopeptides AB (publ), Attn: Oncopeptides Nomination Committee, Luntmakargatan 46, SE-111 37 Stockholm, Sweden.

A proposal must reach the nomination committee no later than by March 31, 2025, to be included in the notice to attend and the agenda for the annual general meeting.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)

E-mail: david.augustsson@oncopeptides.com

Cell phone: +46 76 229 38 68

About Oncopeptides

Oncopeptides is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com

Attachments

[Oncopeptides announces the Nomination Committee](#)